

Brigatinib

Brigatinib (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor)

Brigatinib, a next-generation **ALK inhibitor**, shows promising activity in **Anaplastic lymphoma kinase non small cell lung cancer** that have previously received **crizotinib** with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naïve patients ¹⁾.

¹⁾

Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. *Future Oncol*. 2018 Feb 16. doi: 10.2217/fon-2017-0545. [Epub ahead of print] PubMed PMID: 29451020.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=brigatinib>

Last update: **2024/06/07 03:00**

